Equities
  • Price (CHF)523.80
  • Today's Change-10.20 / -1.91%
  • Shares traded107.59k
  • 1 Year change-10.74%
  • Beta1.2512
Data delayed at least 15 minutes, as of Apr 16 2024 14:53 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.

  • Revenue in CHF (TTM)6.72bn
  • Net income in CHF654.00m
  • Incorporated2002
  • Employees18.00k
  • Location
    Lonza Group AGMuenchensteinerstrasse 38BASEL 4002SwitzerlandCHE
  • Phone+41 613168111
  • Fax+41 613169111
  • Websitehttps://www.lonza.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
LONN:SWX since
announced
Transaction
value
Genentech Inc-Biologics Manufacturing Facility,Vacaville,CaliforniaAnnounced20 Mar 202420 Mar 2024Announced8.63%1.20bn
Synaffix BVDeal completed01 Jun 202301 Jun 2023Deal completed-8.01%171.01m
Data delayed at least 15 minutes, as of Apr 16 2024 14:53 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Qiagen NV1.80bn312.64m8.04bn5.97k26.182.3216.064.471.441.448.2716.190.31691.935.38310,075.805.505.416.606.5362.7764.6517.3716.351.62--0.2839---8.235.53-19.3512.381.55--
Ipsen SA3.22bn600.43m8.84bn5.07k14.662.3412.802.757.397.7239.6646.290.5541.995.23--10.489.7113.9313.3382.7282.7618.9116.020.98930.430.110619.874.757.084.039.75-8.653.71
Recordati Industria Chmc Frmctc SpA2.03bn378.70m10.17bn4.46k26.556.1119.445.021.881.8810.088.190.50751.595.16467,414.409.4811.6712.4015.0268.3270.4318.6921.450.7958.340.517542.4612.369.0224.614.5081.685.46
Eurofins Scientific SE6.34bn502.55m11.38bn61.80k23.222.2910.321.802.611.3032.9226.440.621336.204.79105,417.605.417.496.709.3620.9323.788.7111.231.388.430.433219.28-2.9411.49-21.5310.918.5811.66
Sandoz Group AG-100.00bn-100.00bn12.10bn23.85k------------------------------------------------7.23---90.92------
BioMerieux SA3.58bn347.94m12.12bn14.65k34.963.3120.203.393.013.0130.9331.760.70361.975.00250,815.606.189.307.8812.3155.9956.518.7812.381.19--0.121517.762.398.70-20.956.878.3619.42
Genmab A/S2.15bn567.59m17.75bn2.20k31.164.25--8.2666.0566.05249.95483.850.5037--3.097,474,592.0013.3117.4314.2518.5955.82--26.4235.8713.32--0.0238--13.5740.35-20.1824.21-4.66--
argenx SE1.12bn-270.27m20.74bn1.15k--5.50--18.46-4.84-4.8420.2565.170.31950.43733.721,005,665.00-7.69-17.65-8.49-19.7990.39---24.06-97.729.01--0.0049--198.56117.2558.42--122.32--
UCB SA5.11bn333.73m22.61bn9.08k67.852.5322.474.421.761.7626.9147.300.33451.764.63578,223.102.185.032.676.2867.5072.216.5312.660.92243.140.252936.44-4.802.54-18.33-15.41-1.512.36
Bayer AG46.35bn-2.86bn25.29bn99.72k--0.78953.490.5457-2.99-2.9948.4933.520.39511.434.85477,693.20-2.44-1.79-3.34-2.3858.5459.02-6.18-4.800.80153.400.5764---6.115.33-170.87--1.19-47.66
HALEON PLC12.87bn1.19bn33.65bn24.00k28.691.8048.152.620.11280.11281.221.800.32823.155.76470,916.703.23--3.73--61.59--9.83--0.73497.370.3611--4.09---1.04------
Lonza Group AG6.72bn654.00m39.77bn18.00k60.234.0732.365.928.878.8791.16131.070.39282.805.84373,166.703.835.074.646.2129.0039.159.7514.521.2011.860.227530.577.943.92-46.17-0.030623.957.78
Data as of Apr 16 2024. Currency figures normalised to Lonza Group AG's reporting currency: Swiss Franc CHF

Institutional shareholders

18.72%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 05 Apr 20242.62m3.52%
Norges Bank Investment Managementas of 12 Apr 20242.23m2.99%
UBS Asset Management Switzerland AGas of 02 Apr 20241.91m2.56%
Capital Research & Management Co. (World Investors)as of 31 Dec 20231.42m1.91%
BlackRock Fund Advisorsas of 04 Apr 20241.19m1.60%
Z�rcher Kantonalbank (Investment Management)as of 29 Feb 20241.06m1.42%
BlackRock Investment Management (UK) Ltd.as of 29 Feb 2024902.72k1.21%
Invesco Advisers, Inc.as of 29 Feb 2024887.58k1.19%
Schroder Investment Management Ltd.as of 29 Feb 2024875.08k1.18%
BlackRock Advisors (UK) Ltd.as of 04 Apr 2024852.17k1.14%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.